Behind the Science: CEO of ScanCell, Lindy Durrant on the Company's Breakthrough Antibody Evaluation

04/09/2024 28 min Episodio 25
Behind the Science: CEO of ScanCell, Lindy Durrant on the Company's Breakthrough Antibody Evaluation

Listen "Behind the Science: CEO of ScanCell, Lindy Durrant on the Company's Breakthrough Antibody Evaluation"

Episode Synopsis


In this episode of the All Points West podcast, we sit down with Lindy Durrant, the founder and CEO of AIM-listed ScanCell. Since co-founding ScanCell in 1997, Lindy has been at the forefront of developing groundbreaking immunotherapies for cancer and infectious diseases. With over 25 years of experience in translational research, she has played a pivotal role in bringing monoclonal antibodies and cancer vaccines from the lab to clinical trials. We discuss the rapidly growing immuno-oncology market, the potential of ScanCell's GlyMab platform, and what the future holds for cancer treatment. 

More episodes of the podcast All Points West